Business Context and Reporting Period
This Form 8-K is filed by Galena Biopharma, Inc. (noting the input metadata references SELLAS Life Sciences Group, Inc., but the filing text identifies Galena Biopharma, Inc.) on October 26, 2011. The report addresses a material error discovered during the preparation of a Form S-1 registration statement by its subsidiary, RXi Pharmaceuticals Corporation. The error pertains to the consolidated financial statements for the quarter ended June 30, 2011.
Key Financial Metrics and Restatement
The filing details a restatement of financial results for the period ended June 30, 2011, due to an incorrect calculation of stock volatility used in the Black-Scholes option-pricing model for stock options and warrants.
| Metric | Originally Reported | Restated Value |
|---|---|---|
| Net Loss (3 months ended June 30, 2011) | $1,382,000 | $3,754,000 |
| Net Loss (6 months ended June 30, 2011) | $5,227,000 | $7,599,000 |
| Warrant Liability (Current) | $11,882,000 | $14,254,000 |
| Stock Option Liability (Current) | $682,000 | $1,036,000 |
| Other Income (3 months) | Not specified | $871,000 |
| Other Income (6 months) | Not specified | $2,306,000 |
The filing text does not provide clear values for total revenue, operating cash flow, or liquidity ratios beyond the specific liability adjustments noted above.
Material Changes Versus Prior Period
The material change is the restatement of the Q2 2011 financials. The originally reported weighted-average stock volatility was 74.52%, whereas the correct figure is 98.63%. This error resulted in an understatement of liabilities and an understatement of net losses. The adjustment to the stock option liability is a reclassification of additional paid-in capital and did not impact other income or net loss, but the warrant liability adjustment significantly increased the reported net loss.
Management Commentary, Risks, and Controls
Material Weakness: Management identified a material weakness in internal controls over financial reporting. The error occurred because the spreadsheet used to calculate weighted-average volatility inadvertently omitted one company from a four-company peer group.
Corrective Measures: The company is filing an amendment to its Form 10-Q to restate the financials. Management believes the weakness has been remedied and intends to enhance internal reviews of fair values for stock options and warrants.
Risks: Management warns that failure to improve internal controls could lead to a loss of investor confidence and a negative impact on the trading price of common stock. The Audit Committee and executive officers have discussed these matters with the independent auditor, BDO USA, LLP.
Investor Verification Checklist
- Verify the amended Form 10-Q for the quarter ended June 30, 2011, to confirm the restated financial figures.
- Review the updated Form S-1 registration statement filed by the RXi Pharmaceuticals Corporation subsidiary.
- Assess the company's updated methodology for selecting peer group companies for volatility calculations.
- Monitor future filings for any additional disclosures regarding the effectiveness of remediated internal controls.